Stockholders' Equity	12 Months Ended
Dec. 31, 2019
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 6: Stockholders’ Equity In July 2017, the Company sold to certain institutional investors an aggregate of 66,250 shares of common stock at a purchase price of $34.00 per share, for aggregate proceeds to the Company of $1,987,000, net of transaction expenses. In a concurrent private placement, the Company also sold to each of the purchasers a warrant to purchase one half of a share of the common stock for each share purchased for cash in the offering, pursuant to a common stock purchase warrant, by and between the Company and each Purchaser (each, a “Warrant,” and collectively, the “Warrants”) representing in the aggregate rights to purchase 33,125 shares of common stock at the exercise price. The Warrants became exercisable on January 6, 2018 at an exercise price of $47.00 per share and will expire on January 6, 2023. In October 2018, the Company completed a public offering of securities registered under an effective registration statement filed pursuant to the Securities Act of 1933, as amended. The gross proceeds from the offering were approximately $11.1 million of which $7.4 million was used to pay a portion of the principal amount of the Notes (see Note 11). In the offering, the Company sold 1,845,540 units, consisting of 403,250 common units, at a price to the public of $6.00 per unit, and 1,442,290 pre-funded units, at a price to the public of $6.00 per unit. Each common unit consisted of one share of common stock and a warrant to purchase one share of common stock (“common stock warrant”), and each pre-funded unit consisted of a pre-funded warrant to purchase one share of common stock for $0.02 per share and a common stock warrant. The common stock warrants were immediately exercisable at an exercise price of $6.00 per share (subject to adjustment) and expire on October 4, 2023. By their terms, the common stock warrants cannot be exercised at any time that the warrant holder would beneficially own, after such exercise, more than 9.99% of the outstanding shares of common stock. The common stock warrants are subject to adjustment, if, at any time while the common stock warrants are outstanding, the Company sells or grants any option to purchase, or sells or grants any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any common stock or common stock equivalents, at an effective price per share that is less than the exercise price then in effect, the applicable exercise price shall be reduced, but not below $2.40 per share (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions). The exercise price adjustment provisions of the common stock warrants do not apply to certain ordinary course of business transactions, such as awards of equity securities to employees of the Company, and conversions or exercises of currently outstanding securities previously issued by the Company. As of December 31, 2019, 115,539 pre-funded warrants and 1,845,540 common stock warrants remained outstanding and exercisable. Stockholder Rights Plan In November 2010, the Company executed a rights agreement in connection with the declaration by the Company’s board of directors of a dividend of one preferred stock purchase right (a Right) to be paid on November 10, 2010 (the Record Date) for each share of the Company’s common stock issued and outstanding at the close of business on the Record Date. Each Right entitles the registered holder to purchase one one-thousandth of a share of Series AA Preferred Stock, $0.01 par value per share (a Preferred Share), of the Company at a price of $4.80 per one one-thousandth of a Preferred Share, subject to adjustment. The rights will not be exercisable until a third party acquires 15% of the Company’s common stock or commences or announces its intent to commence a tender offer for at least 15% of the common stock.

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Note 6: Stockholders’ Equity

In July 2017, the Company sold to certain institutional investors an aggregate of 66,250 shares of common stock at a purchase price of $34.00 per share, for aggregate proceeds to the Company of $1,987,000, net of transaction expenses.

In a concurrent private placement, the Company also sold to each of the purchasers a warrant to purchase one half of a share of the common stock for each share purchased for cash in the offering, pursuant to a common stock purchase warrant, by and between the Company and each Purchaser (each, a “Warrant,” and collectively, the “Warrants”) representing in the aggregate rights to purchase 33,125 shares of common stock at the exercise price. The Warrants became exercisable on January 6, 2018 at an exercise price of $47.00 per share and will expire on January 6, 2023.

In October 2018, the Company completed a public offering of securities registered under an effective registration statement filed pursuant to the Securities Act of 1933, as amended. The gross proceeds from the offering were approximately $11.1 million of which $7.4 million was used to pay a portion of the principal amount of the Notes (see Note 11). In the offering, the Company sold 1,845,540 units, consisting of 403,250 common units, at a price to the public of $6.00 per unit, and 1,442,290 pre-funded units, at a price to the public of $6.00 per unit. Each common unit consisted of one share of common stock and a warrant to purchase one share of common stock (“common stock warrant”), and each pre-funded unit consisted of a pre-funded warrant to purchase one share of common stock for $0.02 per share and a common stock warrant. The common stock warrants were immediately exercisable at an exercise price of $6.00 per share (subject to adjustment) and expire on October 4, 2023. By their terms, the common stock warrants cannot be exercised at any time that the warrant holder would beneficially own, after such exercise, more than 9.99% of the outstanding shares of common stock. The common stock warrants are subject to adjustment, if, at any time while the common stock warrants are outstanding, the Company sells or grants any option to purchase, or sells or grants any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any common stock or common stock equivalents, at an effective price per share that is less than the exercise price then in effect, the applicable exercise price shall be reduced, but not below $2.40 per share (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions). The exercise price adjustment provisions of the common stock warrants do not apply to certain ordinary course of business transactions, such as awards of equity securities to employees of the Company, and conversions or exercises of currently outstanding securities previously issued by the Company. As of December 31, 2019, 115,539 pre-funded warrants and 1,845,540 common stock warrants remained outstanding and exercisable.

Stockholder Rights Plan

In November 2010, the Company executed a rights agreement in connection with the declaration by the Company’s board of directors of a dividend of one preferred stock purchase right (a Right) to be paid on November 10, 2010 (the Record Date) for each share of the Company’s common stock issued and outstanding at the close of business on the Record Date. Each Right entitles the registered holder to purchase one one-thousandth of a share of Series AA Preferred Stock, $0.01 par value per share (a Preferred Share), of the Company at a price of $4.80 per one one-thousandth of a Preferred Share, subject to adjustment. The rights will not be exercisable until a third party acquires 15% of the Company’s common stock or commences or announces its intent to commence a tender offer for at least 15% of the common stock.